Illinois Municipal Retirement Fund Has $778,000 Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Illinois Municipal Retirement Fund trimmed its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,959 shares of the company’s stock after selling 431 shares during the period. Illinois Municipal Retirement Fund’s holdings in Amphastar Pharmaceuticals were worth $778,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Aurora Investment Counsel grew its holdings in shares of Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock valued at $2,654,000 after buying an additional 232 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after acquiring an additional 301 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its position in Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares during the period. KBC Group NV grew its stake in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after acquiring an additional 650 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its holdings in shares of Amphastar Pharmaceuticals by 8.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock valued at $466,000 after purchasing an additional 801 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the sale, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on AMPH. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price for the company. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average target price of $50.33.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $27.52 on Tuesday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $26.98 and a fifty-two week high of $53.96. The stock’s 50-day moving average is $34.74 and its two-hundred day moving average is $42.57. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market cap of $1.32 billion, a P/E ratio of 9.17, a PEG ratio of 2.19 and a beta of 0.81.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.